Acorda Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Amortization of net premiums and discounts on investments
Amortization of debt discount and debt issuance costs
Depreciation and amortization expense
Intangible asset impairments
Loss on assets held for sale
Intangible asset impairment
Change in contingent consideration obligation
Change in derivative liability
Realized gain on foreign currency transaction
Gain on disposal of property and equipment
Non-cash lease expense
Gain on debt extinguishment
Non-cash royalty revenue
Deferred tax provision (benefit)

Changes in assets and liabilities:
Decrease (increase) in accounts receivable
Increase in prepaid expenses and other current assets
Decrease (increase) in inventory
Increase in other assets
Increase (decrease) in accounts payable, accrued expenses and other current liabilities
Increase (decrease) in other non-current liabilities
Net cash (used) in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of intangible assets
Purchases of investments
Proceeds from maturities of investments
Proceeds from sale of Chelsea facility, net
Net cash provided by investing activities

Cash flows from financing activities:
Repayment of Convertible Senior Notes Due 2021
Debt issuance costs
Proceeds from issuance of common stock and option exercises
Purchase of treasury stock
Repayment of loans payable
Net cash (used) in financing activities

Effect of exchange rate changes on cash and cash equivalents and restricted cash
Net (decrease) in cash and cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure:
Non-cash debt issuance cost
Cash paid for interest
Cash paid for taxes

Comments